Eloxx Pharma Board approves retention program with performance-based equity grants to CEO

Eloxx Pharmaceuticals, Inc.

CEO Sumit Aggarwal granted 75,000 performance RSUs and 25,000 performance stock options (exercise price $4.63).
Awards vest upon earliest of: $35M market cap, $25M capital raise, or change in control.
Future grants of 60,000 RSUs to CEO and 20,000 RSUs to Head of R&D Vijay Modur, subject to share availability.
Additional 50,000 stock option for CEO under same condition, with exercise price not greater than $4.63.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.